216 related articles for article (PubMed ID: 36925390)
41. Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials.
Que Y; Xu M; Xu Y; Almeida VDF; Zhu L; Wang Z; Wang Y; Liu X; Jiang L; Wang D; Li C; Zhou J
Front Immunol; 2021; 12():755866. PubMed ID: 34777368
[TBL] [Abstract][Full Text] [Related]
42. B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta-analysis.
Gagelmann N; Ayuk F; Atanackovic D; Kröger N
Eur J Haematol; 2020 Apr; 104(4):318-327. PubMed ID: 31883150
[TBL] [Abstract][Full Text] [Related]
43. A transgene-encoded truncated human epidermal growth factor receptor for depletion of anti- B-cell maturation antigen CAR-T cells.
Wang Q; He F; He W; Huang Y; Zeng J; Zi F; Zheng J; Fei Y; Xu J; Song Y; Ye X; Lai R; Ye L; Zhu B
Cell Immunol; 2021 May; 363():104342. PubMed ID: 33765541
[TBL] [Abstract][Full Text] [Related]
44. GPRC5D-Targeted CAR T Cells for Myeloma.
Mailankody S; Devlin SM; Landa J; Nath K; Diamonte C; Carstens EJ; Russo D; Auclair R; Fitzgerald L; Cadzin B; Wang X; Sikder D; Senechal B; Bermudez VP; Purdon TJ; Hosszu K; McAvoy DP; Farzana T; Mead E; Wilcox JA; Santomasso BD; Shah GL; Shah UA; Korde N; Lesokhin A; Tan CR; Hultcrantz M; Hassoun H; Roshal M; Sen F; Dogan A; Landgren O; Giralt SA; Park JH; Usmani SZ; Rivière I; Brentjens RJ; Smith EL
N Engl J Med; 2022 Sep; 387(13):1196-1206. PubMed ID: 36170501
[TBL] [Abstract][Full Text] [Related]
45. Current use of CAR T cells to treat multiple myeloma.
Firestone RS; Mailankody S
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):340-347. PubMed ID: 38066841
[TBL] [Abstract][Full Text] [Related]
46. Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial.
Xia J; Li H; Yan Z; Zhou D; Wang Y; Qi Y; Cao J; Li D; Cheng H; Sang W; Zhu F; Sun H; Chen W; Qi K; Yan D; Qiu T; Qiao J; Yao R; Liu Y; Wang X; Zhang Y; Peng S; Huang CH; Zheng J; Li Z; Chang AH; Xu K
J Clin Oncol; 2023 May; 41(14):2583-2593. PubMed ID: 36881785
[TBL] [Abstract][Full Text] [Related]
47. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.
Shah N; Chari A; Scott E; Mezzi K; Usmani SZ
Leukemia; 2020 Apr; 34(4):985-1005. PubMed ID: 32055000
[TBL] [Abstract][Full Text] [Related]
48. Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy.
Van Oekelen O; Nath K; Mouhieddine TH; Farzana T; Aleman A; Melnekoff DT; Ghodke-Puranik Y; Shah GL; Lesokhin A; Giralt S; Thibaud S; Rossi A; Rodriguez C; Sanchez L; Richter J; Richard S; Cho HJ; Chari A; Usmani SZ; Jagannath S; Shah UA; Mailankody S; Parekh S
Blood; 2023 Feb; 141(7):756-765. PubMed ID: 36327160
[TBL] [Abstract][Full Text] [Related]
49. Treatment of Multiple Myeloma Using Chimeric Antigen Receptor T Cells with Dual Specificity.
Globerson Levin A; Rawet Slobodkin M; Waks T; Horn G; Ninio-Many L; Deshet Unger N; Ohayon Y; Suliman S; Cohen Y; Tartakovsky B; Naparstek E; Avivi I; Eshhar Z
Cancer Immunol Res; 2020 Dec; 8(12):1485-1495. PubMed ID: 33008840
[TBL] [Abstract][Full Text] [Related]
50. Preclinical Efficacy of BCMA-Directed CAR T Cells Incorporating a Novel D Domain Antigen Recognition Domain.
Buonato JM; Edwards JP; Zaritskaya L; Witter AR; Gupta A; LaFleur DW; Tice DA; Richman LK; Hilbert DM
Mol Cancer Ther; 2022 Jul; 21(7):1171-1183. PubMed ID: 35737298
[TBL] [Abstract][Full Text] [Related]
51. In Vitro Functionality and Endurance of GMP-Compliant Point-of-Care BCMA.CAR-T Cells at Different Timepoints of Cryopreservation.
Jiang G; Neuber B; Hückelhoven-Krauss A; Höpken UE; Ding Y; Sedloev D; Wang L; Reichman A; Eberhardt F; Wermke M; Rehm A; Müller-Tidow C; Schmitt A; Schmitt M
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338672
[TBL] [Abstract][Full Text] [Related]
52. Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis.
Yang Q; Li X; Zhang F; Yang Q; Zhou W; Liu J
Int J Med Sci; 2021; 18(8):1786-1797. PubMed ID: 33746596
[No Abstract] [Full Text] [Related]
53. BCMA in Multiple Myeloma-A Promising Key to Therapy.
Kleber M; Ntanasis-Stathopoulos I; Terpos E
J Clin Med; 2021 Sep; 10(18):. PubMed ID: 34575199
[TBL] [Abstract][Full Text] [Related]
54. Novel BCMA-OR-CD38 tandem-dual chimeric antigen receptor T cells robustly control multiple myeloma.
Feng Y; Liu X; Li X; Zhou Y; Song Z; Zhang J; Shi B; Wang J
Oncoimmunology; 2021; 10(1):1959102. PubMed ID: 34434610
[TBL] [Abstract][Full Text] [Related]
55. Comparison of FACS and PCR for Detection of BCMA-CAR-T Cells.
Reichman A; Kunz A; Joedicke JJ; Höpken UE; Keib A; Neuber B; Sedloev D; Wang L; Jiang G; Hückelhoven-Krauss A; Eberhardt F; Müller-Tidow C; Wermke M; Rehm A; Schmitt M; Schmitt A
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055086
[TBL] [Abstract][Full Text] [Related]
56. BCMA-targeting approaches for treatment of multiple myeloma.
Chen Y; Nagarajan C; Tan MS; Martinelli G; Cerchione C
Panminerva Med; 2021 Mar; 63(1):28-36. PubMed ID: 32955181
[TBL] [Abstract][Full Text] [Related]
57. Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease.
Deng H; Liu M; Yuan T; Zhang H; Cui R; Li J; Yuan J; Wang X; Wang Y; Deng Q
Front Immunol; 2021; 12():720571. PubMed ID: 34421924
[TBL] [Abstract][Full Text] [Related]
58. Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization.
Camviel N; Wolf B; Croce G; Gfeller D; Zoete V; Arber C
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36323436
[TBL] [Abstract][Full Text] [Related]
59. [Humanized BCMA CAR-T cell salvage therapy in two refractory multiple myeloma patients who progressed after their murine BCMA CAR-T cell therapy].
Cui R; Li P; Li Q; Mu J; Jiang YL; Jiang YY; Deng Q
Zhonghua Xue Ye Xue Za Zhi; 2021 Jun; 42(6):502-507. PubMed ID: 34384157
[No Abstract] [Full Text] [Related]
60. CAR T cell therapies for patients with multiple myeloma.
Mikkilineni L; Kochenderfer JN
Nat Rev Clin Oncol; 2021 Feb; 18(2):71-84. PubMed ID: 32978608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
